| Risk | Impact on Prophylaxis | Impact on Laboratory Monitoring | |
|---|---|---|---|
| Bacterial Infections | No increased risk during induction (29) | Standard prophylaxis | None |
| BK Virus | No increased risk | N/A | Standard BK screening protocols |
| CMV | No increased risk during induction (43, 20) increased risk compared to ATG during rejection therapy (6) | Standard prophylaxis or preemptive protocols | None |
| EBV / PTLD | No increased risk (43, 29) | N/A | Standard EBV screening protocols for EBV D+/R- SOT recipients |
| Fungal Infections | No increased risk (6) | None | None |
| HCV/HBV | Data is mixed, demonstrating both increased risk and no risk of recurrent HCV infection | N/A for HCV, Follow standard protocols for HBV prophylaxis | Standard monitoring |
| HSV/HZV | No increased risk | None | None |
| Pneumocystis | No increased risk (6, 8, 33) | Standard prophylaxis | N/A |